Literature DB >> 18696182

Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.

Sana Intidhar Labidi1, Catherine Sebban2, Hervé Ghesquières2, Emmanuele Virelizier Nicolas2, Pierre Biron2.   

Abstract

We report the case of a 58-year-old man with multiple myeloma stage III A who received tandem autologous stem cell transplantation after induction by two courses of VAD and three cycles of bortezomib-dexamethasone, due to progression under chemotherapy. The second transplantation was complicated by severe hepatic veno-occlusive disease (HVOD). The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18696182     DOI： 10.1007/s12185-008-0152-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  11 in total

Review 1.  Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.

Authors:  Martha Wadleigh; Vincent Ho; Parisa Momtaz; Paul Richardson
Journal:  Curr Opin Hematol       Date:  2003-11       Impact factor: 3.284

2.  Pulmonary veno-occlusive disease as a cause for reversible pulmonary hypertension in a patient with multiple myeloma undergoing peripheral blood stem cell transplantation.

Authors:  Pankaj Malhotra; Subhash Varma; Neelam Varma; Rati Ram Sharma; Sanjay Jain; Savita Kumari; Rohit Manoj; Neelam Marwaha
Journal:  Am J Hematol       Date:  2005-10       Impact factor: 10.047

3.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Authors:  Jean-Luc Harousseau; Michel Attal; Xavier Leleu; Jacques Troncy; Brigitte Pegourie; Anne-Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Jean-Gabriel Fuzibet; Marc Renaud; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

4.  Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

Authors:  A Alegre; J Díaz-Mediavilla; J San-Miguel; R Martínez; J García Laraña; A Sureda; J J Lahuerta; D Morales; J Bladé; D Caballero; J De la Rubia; A Escudero; J L Díez-Martín; F Hernández-Navarro; J Rifón; J Odriozola; S Brunet; J De la Serna; J Besalduch; M J Vidal; C Solano; A Leon; J J Sánchez; C Martínez-Chamorro; J M Fernández-Rañada
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

5.  The syndrome of hepatic veno-occlusive disease after marrow transplantation.

Authors:  S I Bearman
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

6.  Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Authors:  Laura Rosiñol; Albert Oriol; Maria Victoria Mateos; Anna Sureda; Pedro García-Sánchez; Norma Gutiérrez; Adrián Alegre; Juan José Lahuerta; Javier de la Rubia; Carlos Herrero; Xiangyang Liu; Helgi Van de Velde; Jesús San Miguel; Joan Bladé
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

7.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

8.  Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.

Authors:  G B McDonald; M S Hinds; L D Fisher; H G Schoch; J L Wolford; M Banaji; B J Hardin; H M Shulman; R A Clift
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

9.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Authors:  Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert Soiffer; Thomas Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James Vredenburgh; Allen R Chen; Sally Arai; Georgia Vogelsang; George B McDonald; Eva C Guinan
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245
View more
  3 in total

1.  A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Authors:  A Dispenzieri; A D'Souza; M A Gertz; K Laumann; G Wiseman; M Q Lacy; B LaPlant; F Buadi; S R Hayman; S K Kumar; D Dingli; W J Hogan; S M Ansell; D A Gastineau; D J Inwards; I N Micallef; L F Porrata; P B Johnston; M R Litzow; T E Witzig
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

2.  Veno-occlusive disease following high dose melphalan.

Authors:  Tuphan Kanti Dolai; K S Nataraj; Maitreyee Bhattacharya; Malay Kumar Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-18       Impact factor: 0.900

3.  Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia.

Authors:  Athanasios Papadopoulos; George Ntaios; Georgia Kaiafa; Fotios Girtovitis; Zoi Saouli; Zisis Kontoninas; Michael D Diamantidis; Christos Savopoulos; Apostolos Hatzitolios
Journal:  Int J Hematol       Date:  2008-10-07       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.